Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure.

Abstract	Metastatic melanoma is one of the most deadly forms of cancer and is poorly responsive to standard chemotherapeutics, such as Dacarbazine and Paclitaxel. Recently, the advent of Vemurafenib and Ipilimumab has broadened the spectrum of therapeutic options for advanced melanoma patients but the occurrence of resistance and of high-grade toxicities call for better and more effective treatments. This review focuses on approved and experimental therapies for metastatic melanoma. The mechanism of action and the reported efficacy data for small molecule drugs and biologics are discussed, outlining directions for future pharmaceutical research in this field.
Authors	Francesca Pretto, Dario Neri
Journal	Pharmacology & therapeutics (Pharmacol Ther) Vol. 139 Issue 3 Pg. 405-11 (Sep 2013) ISSN: 1879-016X [Electronic] England
PMID	23711792 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright	Copyright © 2013 Elsevier Inc. All rights reserved.
Chemical References	Antineoplastic Agents
Topics	Animals Antineoplastic Agents (adverse effects, pharmacology, therapeutic use) Drug Approval Drug Design Drug Resistance, Neoplasm Humans Melanoma (drug therapy, pathology) Neoplasm Metastasis Skin Neoplasms (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!